Sativex (THC:CBD spray) is approved in 30+ countries for MS spasticity. The strongest regulatory validation outside the US.
Multiple sclerosis causes debilitating spasticity, pain, and bladder dysfunction. Sativex — a 1:1 THC:CBD oromucosal spray — is approved in over 30 countries for MS spasticity, representing the most internationally validated cannabis medicine.
Medical Disclaimer: This information is for educational purposes only. Consult a qualified healthcare provider before using cannabis for Multiple Sclerosis. Find a cannabis-knowledgeable provider →
Multiple sclerosis is a chronic autoimmune disease affecting 1 million Americans. It causes demyelination of nerve fibers, leading to spasticity, pain, fatigue, bladder dysfunction, and cognitive impairment. Spasticity — painful muscle stiffness and spasms — affects 80% of MS patients and is one of the most debilitating symptoms.
Sativex (nabiximols), a 1:1 THC:CBD oromucosal spray, is approved for MS spasticity in over 30 countries including Canada, the UK, and most of Europe. Multiple Phase III clinical trials demonstrated significant reductions in spasticity scores, pain, and sleep disturbance. This represents the most internationally validated cannabis medicine in existence.
The endocannabinoid system is deeply involved in MS pathology. CB1 and CB2 receptors are upregulated in MS lesions, and endocannabinoid levels are elevated in the cerebrospinal fluid of MS patients — suggesting the body is attempting to use its own cannabinoid system to manage the disease.
Beyond spasticity, cannabis addresses multiple MS symptoms: neuropathic pain (very common in MS), bladder dysfunction, sleep disruption, and depression. The multi-symptom efficacy of cannabis is particularly valuable in MS, where patients often manage 5–10 concurrent symptoms.
THC and CBD act on CB1 receptors in the spinal cord and motor cortex to reduce spasticity and muscle spasms. CB2 receptor activation reduces neuroinflammation and may slow demyelination. Cannabis addresses neuropathic pain through CB1-mediated suppression of pain signaling. Bladder dysfunction improves through CB1/CB2 modulation of bladder smooth muscle and sensory nerves.
Our editorial team has tested hundreds of cannabis products for multiple sclerosis management. These brands consistently deliver the highest quality formulations with transparent lab testing.
World-leading scientist formulation. Standardized full spectrum profiles, not just a CBD count. Pioneered the cannabis topical liniment spray.
Liniment spray is the most effective topical staff have tested.
Best For
Same world-leading scientist as CBDWellness. Verified THC non-detect on every batch by ISO 17025 accredited lab — trusted by military, athletes, and law enforcement.
The only broad spectrum brand staff trust for drug-tested professionals.
Best For
Same world-leading scientist as CBDWellness. Standardized THC formulations for consistent, reliable therapeutic effects. Available at licensed dispensaries.
THC topical liniment spray is the most effective cannabis topical staff have tested.
Best For
Editorial Disclosure: These brands are selected by our editorial team based on independent staff testing, lab result analysis, and 7 years of annual awards data. We do not accept payment for editorial placement. See our Annual Awards methodology for full details.